SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION ARTICLE M impact

Intellia says FDA accepted BLA for lonvo-z

Intellia said the FDA accepted the BLA for lonvo-z, granted Priority Review and set a PDUFA action date of March 10, 2027.

NTLA

Intellia announced FDA acceptance of the BLA for lonvo-z and Priority Review with a PDUFA action date of March 10, 2027.Key Highlights:Original SEC Filing: Intellia Therapeutics, Inc. [ NTLA ] - 8-K - Sep. 08, 2026This is an AI-powered summary. It may contain inaccuracies.

Consider verifying import…

Related stories